BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...Co. and RA Capital Management and existing investors Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners...
BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...prior CEO, Niall O’Donnell, will remain on its board. He is a managing director at RiverVest Venture Partners...
...others. Returning investors include New Enterprise Associates, Pappas Capital and Lundbeckfonden Ventures, as well as RiverVest.TARGETSPPARδ...
BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

...to move forward. The company’s investors include Arix, BioMed Ventures, New Enterprise Associates, Pappas Capital, RiverVest Venture Partners...
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

...participation from existing investors New Enterprise Associates, Arix Bioscience plc (LSE:ARIX), Lundbeckfonden Ventures, Pappas Capital, RiverVest Venture Partners...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners, Novo Holdings A/S, RiverVest Venture Partners...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...led the financing with participation from fellow new investors SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners...
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

...Spruce Biosciences Inc., announced late Wednesday. Joining them were existing investors Novo Holdings A/S and RiverVest Venture Partners...
BioCentury | Jun 22, 2019
Financial News

Mirum, Fulcrum file for IPOs

...a 17.3% share. Other shareholders are Novo Holdings A/S with 10.4%, Shire with 10.3%, and RiverVest...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...to New Enterprise Associates, other investors in the round include Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners...
...employees: 9 Funds raised: $50 million Investors: New Enterprise Associates, Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners...
BioCentury | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

...protein α (SIRPA; CD172a; SHPS-1) mAb. Lightchain led the round with participation from existing investors RiverVest Venture Partners...
Items per page:
1 - 10 of 100
BioCentury | Feb 25, 2021
Deals

Feb. 24 Quick Takes: ICON buying PRA in $12B CRO deal; plus venture rounds for Yisheng, Xilio, Truvian, Lyvgen, AmacaThera, and more

...Co. and RA Capital Management and existing investors Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners...
BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...prior CEO, Niall O’Donnell, will remain on its board. He is a managing director at RiverVest Venture Partners...
...others. Returning investors include New Enterprise Associates, Pappas Capital and Lundbeckfonden Ventures, as well as RiverVest.TARGETSPPARδ...
BioCentury | Jul 21, 2020
Product Development

Amplyx’s first-in-class antifungal heads for a head-to-head study

...to move forward. The company’s investors include Arix, BioMed Ventures, New Enterprise Associates, Pappas Capital, RiverVest Venture Partners...
BioCentury | May 19, 2020
Finance

May 19 Quick Takes: Cowen closes $493M fund; plus Guangzhou BeBetter, Fountain Therapeutics, Amplyx, ChromaCode, Applied Molecular

...participation from existing investors New Enterprise Associates, Arix Bioscience plc (LSE:ARIX), Lundbeckfonden Ventures, Pappas Capital, RiverVest Venture Partners...
BioCentury | Apr 28, 2020
Finance

April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic

...from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners, Novo Holdings A/S, RiverVest Venture Partners...
BioCentury | Mar 2, 2020
Finance

Xilio to deploy $100M B round toward POC for tumor-activated immunotherapies

...led the financing with participation from fellow new investors SV Health Investors, MRL Ventures Fund, RiverVest Venture Partners...
BioCentury | Feb 20, 2020
Finance

With $88M series B, Spruce seeks short path to approval in rare endocrine disorder

...Spruce Biosciences Inc., announced late Wednesday. Joining them were existing investors Novo Holdings A/S and RiverVest Venture Partners...
BioCentury | Jun 22, 2019
Financial News

Mirum, Fulcrum file for IPOs

...a 17.3% share. Other shareholders are Novo Holdings A/S with 10.4%, Shire with 10.3%, and RiverVest...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...to New Enterprise Associates, other investors in the round include Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners...
...employees: 9 Funds raised: $50 million Investors: New Enterprise Associates, Lundbeckfonden Ventures, Pappas Capital and RiverVest Venture Partners...
BioCentury | Mar 25, 2019
Financial News

Arch Oncology raises $50M series B to develop anti-CD47 mAb

...protein α (SIRPA; CD172a; SHPS-1) mAb. Lightchain led the round with participation from existing investors RiverVest Venture Partners...
Items per page:
1 - 10 of 100